Clinical Trials (Phase III)
Filter News
Found 12,971 articles
-
The FDA based its decision on data from the COMBI-AD Phase III trial.
-
DBV's share price crumbled over the weekend after its Phase III peanut allergy trial failed to show a statistically significant response against placebo.
-
Boehringer Ingelheim Release: Ofev Demonstrates Consistent Long-Term Efficacy in IPF Regardless of Baseline Lung Function
10/23/2017
Boehringer Ingelheim announced today the presentation of a new analysis on the use of Ofev (nintedanib) in treating people with idiopathic pulmonary fibrosis (IPF) at the 2017 CHEST Annual Meeting.
-
Tigenix Granted Orphan Drug Designation From the U.S. FDA for Cx601
10/23/2017
TiGenix started a global pivotal Phase III clinical trial in the first half of 2017.
-
Achillion Announces Presentation of Data From OMEGA-1 Phase IIb Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting
10/23/2017
98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6.
-
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy in HBV Patients Switched From Viread
10/23/2017
Gilead Sciences, Inc.today announced results from Phase II and Phase III studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection.
-
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma
10/23/2017
NANOBIOTIX announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma.
-
Celgene is scrapping a late-stage Crohn's disease drug it acquired in a $710M deal three years ago following an interim data analysis.
-
DURECT's Posimir (SABER - Bupivacaine) for post-surgical pain failed its Phase III clinical trial.
-
Mis-Matched Expectations With Celgene, Ionis
10/20/2017
-
Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
10/20/2017
Spero plans for a rapid development approach with SPR994.
-
VBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe
10/20/2017
The EMA has designated ofranergene obadenovec (VB-111) as an 'orphan medicinal product' for the treatment of ovarian cancer.
-
Omeros Reports Successful OMS721 Treatment of Patient With Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-Versus-Host Disease
10/20/2017
The results may expand target for Omeros' planned phase 3 program in HCT-TMA.
-
Shionogi Release: Confirmatory Results of the Second Phase 3 Lusutrombopag (S-888711) Study (L-PLUS 2) Presented at the 2017 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD)
10/20/2017
Shionogi announced it will present positive efficacy and safety results from a global Phase 3 study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C.
-
AcelRx's DSUVIA Clinical Trial Results Selected as a Top Abstract for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY 2017
10/20/2017
AcelRx today announced its clinical data presentation on the safety and efficacy of DSUVIA(sufentanil sublingual tablet), 30 mcg classified by age group across four clinical trials at the American Society of Anesthesiologists'(ASA) ANESTHESIOLOGY 2017 Annual Meeting.
-
The company plans to expeditiously advance AMT-061 instead of AMT-060.
-
BioMarin updated the investment community on the Company's development portfolio at R&D Day in New York.
-
Merck's KEYTRUDA (Pembrolizumab) More Than Doubled Median Overall Survival Compared To Chemotherapy After Two Years Of Follow Up In First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer With High Levels Of PD-L1
10/18/2017
Merck announced the presentation of updated overall survival (OS) findings, a secondary endpoint, from the phase 3 KEYNOTE-024 trial evaluating KEYTRUDA (pembrolizumab).
-
Diffusion Pharma Receives Final FDA Protocol Guidance for Phase III Clinical Trial with TSC in Pa...
10/17/2017
The company expects to begin trial by year-end. -
Immune Design Announces Positive FDA Feedback on Phase III Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
10/17/2017
The company plans to initiate a pivotal Phase 3 trial to support a Biologics License Application for CMB305.